Overview

Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
Single-dose cross over comparative bioavailability of Ondansetron 24 mg oDT and Zofran 24 mg ODT
Phase:
Phase 1
Details
Lead Sponsor:
Par Pharmaceutical, Inc.
Collaborator:
Algorithme Pharma Inc
Treatments:
Ondansetron